162 related articles for article (PubMed ID: 34104028)
21. Amyloid transthyretin cardiac amyloidosis: diagnosis and management.
Di Giovanni B; Gustafson D; Delgado DH
Expert Rev Cardiovasc Ther; 2019 Sep; 17(9):673-681. PubMed ID: 31478389
[No Abstract] [Full Text] [Related]
22. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center.
López-Sainz Á; Hernandez-Hernandez A; Gonzalez-Lopez E; Domínguez F; Restrepo-Cordoba MA; Cobo-Marcos M; Gómez-Bueno M; Hernandez-Perez FJ; Oteo JF; Mirelis JG; Cavero MA; Moñivas V; Mingo Santos S; de Haro-Del Moral FJ; Krsnik I; Salas C; Bornstein B; Briceño A; López JA; Vázquez J; Alonso-Pulpón L; Segovia J; Garcia-Pavia P
Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):149-158. PubMed ID: 32317158
[TBL] [Abstract][Full Text] [Related]
23. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Lane T; Fontana M; Martinez-Naharro A; Quarta CC; Whelan CJ; Petrie A; Rowczenio DM; Gilbertson JA; Hutt DF; Rezk T; Strehina SG; Caringal-Galima J; Manwani R; Sharpley FA; Wechalekar AD; Lachmann HJ; Mahmood S; Sachchithanantham S; Drage EPS; Jenner HD; McDonald R; Bertolli O; Calleja A; Hawkins PN; Gillmore JD
Circulation; 2019 Jul; 140(1):16-26. PubMed ID: 31109193
[TBL] [Abstract][Full Text] [Related]
24. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
[TBL] [Abstract][Full Text] [Related]
25. Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis.
Plumadore E; Lombardo L; Cabral KP
Am J Health Syst Pharm; 2022 Jan; 79(2):52-62. PubMed ID: 34491302
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of Positive
Roteta Unceta-Barrenechea A; Melero Polo J; Andrés Gracia A; Revilla Martí P; Menao Guillén S; Lahuerta Pueyo C; Pérez-Palacios R; Moreno Gázquez I; Gutiérrez AG; Aibar Arregui MÁ
Acta Cardiol Sin; 2022 Mar; 38(2):169-174. PubMed ID: 35273438
[TBL] [Abstract][Full Text] [Related]
27. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
28. Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy.
Feng KY; Loungani RS; Rao VN; Patel CB; Khouri MG; Felker GM; DeVore AD
JACC CardioOncol; 2019 Dec; 1(2):273-279. PubMed ID: 34396189
[TBL] [Abstract][Full Text] [Related]
29. A case of cardiac amyloidosis in an elderly Japanese patient with amyloidogenic transthyretin Val122Ile variant.
Ono R; Takahashi H; Sato T; Yamazaki T; Hori Y; Fukushima K
J Cardiol Cases; 2020 Nov; 22(5):221-225. PubMed ID: 33133314
[TBL] [Abstract][Full Text] [Related]
30. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Gillmore JD; Maurer MS; Falk RH; Merlini G; Damy T; Dispenzieri A; Wechalekar AD; Berk JL; Quarta CC; Grogan M; Lachmann HJ; Bokhari S; Castano A; Dorbala S; Johnson GB; Glaudemans AW; Rezk T; Fontana M; Palladini G; Milani P; Guidalotti PL; Flatman K; Lane T; Vonberg FW; Whelan CJ; Moon JC; Ruberg FL; Miller EJ; Hutt DF; Hazenberg BP; Rapezzi C; Hawkins PN
Circulation; 2016 Jun; 133(24):2404-12. PubMed ID: 27143678
[TBL] [Abstract][Full Text] [Related]
31. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
Kittleson MM; Maurer MS; Ambardekar AV; Bullock-Palmer RP; Chang PP; Eisen HJ; Nair AP; Nativi-Nicolau J; Ruberg FL;
Circulation; 2020 Jul; 142(1):e7-e22. PubMed ID: 32476490
[TBL] [Abstract][Full Text] [Related]
32. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.
Pilebro B; Suhr OB; Näslund U; Westermark P; Lindqvist P; Sundström T
Ups J Med Sci; 2016; 121(1):17-24. PubMed ID: 26849806
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
[TBL] [Abstract][Full Text] [Related]
34. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
35. Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience.
Ikram A; Donnelly JP; Sperry BW; Samaras C; Valent J; Hanna M
Amyloid; 2018 Sep; 25(3):197-202. PubMed ID: 30388377
[TBL] [Abstract][Full Text] [Related]
36. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
[TBL] [Abstract][Full Text] [Related]
37. Current Challenges of Cardiac Amyloidosis Awareness among Romanian Cardiologists.
Adam R; Neculae G; Stan C; Jurcut R
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34066384
[TBL] [Abstract][Full Text] [Related]
38. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J; Losada-López I; Cisneros-Barroso E; Garcia-Pavia P; González-Costello J; Muñoz-Beamud F; Campistol JM; Fernandez-Torron R; Chapman D; Amass L
Neurol Ther; 2021 Dec; 10(2):833-845. PubMed ID: 34331265
[TBL] [Abstract][Full Text] [Related]
39. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
Gopal DM; Ruberg FL; Siddiqi OK
Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
[TBL] [Abstract][Full Text] [Related]
40. Transthyretin cardiac amyloidosis in aortic stenosis: Prevalence, diagnostic challenges, and clinical implications.
Balciunaite G; Rimkus A; Zurauskas E; Zaremba T; Palionis D; Valeviciene N; Aidietis A; Serpytis P; Rucinskas K; Sogaard P; Glaveckaite S; Zorinas A; Janusauskas V
Hellenic J Cardiol; 2020; 61(2):92-98. PubMed ID: 31740363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
